Bromo-DMA: the Australasian hallucinogen?
N Buhrich, G Morris, G Cook
Australian & New Zealand Journal of Psychiatry September 1983 DOI: 10.3109/00048678309161284 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case study Case report Peer reviewed |
|---|---|
| Sample size | 2 |
| Population | Two individuals with Bromo-DMA intoxication in Australasia |
| Interventions | Bromo-DMA haloperidol |
| Duration | Recovered within 24 hours |
| Key findings | The authors argue that Bromo-DMA, not LSD as commonly reported by users, may account for most hallucinogen-related toxic states in Australasia if police seizure data reflect ingestion frequency. Two reported cases of Bromo-DMA intoxication both resolved within 24 hours after haloperidol treatment. |
Abstract
If the frequency of seizures by police of hallucinogens reflects the frequency with which various hallucinogens are ingested in Australasia, most toxic states resulting from hallucinogen abuse are due to Bromo-DMA and not to LSD as is commonly reported by the subjects. Two cases of intoxication with the new hallucinogen, Bromo-DMA, are reported. Both recovered within 24 hours following treatment with haloperidol.
Citations in the library
Cited by 3
- Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens. Current Topics in Behavioral Neurosciences 2017
- The Non-Peptide Arginine-Vasopressin v1a Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish Frontiers in Psychiatry August 13, 2017
- 'Designer drugs'. A problem in clinical toxicology. Medical toxicology and adverse drug experience 1988